Bachelor's at Ciências Biológicas from Universidade Estadual Paulista Júlio de Mesquita Filho (2005) and master's at General Biology from Universidade Estadual de Campinas (2008). Has experience in Morphology, focusing on Cytology and Celular Biology, acting on the following subjects: decanoato de nandrolona, esteróide, morfologia, útero and uch rat. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Ovarian cancer (OC) is the second gynecological cancer that affects women and, due to its generic symptoms, it has high rates of recurrence with rapid progression and most patients develop chemoresistance to conventional treatments. Uncontrolled cell proliferation represents one of the characteristics of neoplastic disease and, tumor cells may adjust their energy metabolism in favor of ra…
Ovarian cancer (OC) is the most lethal gynecological malignancy and the fifth leading cause of cancer death, mainly due to the resistance to treatments associated with poor prognosis. Melatonin (Mel), an indoleamine secreted by the pineal gland in the circadian cycle dark phase, has shown a number of antitumor properties both in vitro and in vivo. Evidences suggest that Mel exhibit an onc…
Ovarian cancer (OC) has the highest incidence in postmenopausal women and, due to its late diagnosis and poor prognosis, is the fifth most common cause of cancer death. OC is responsive to chemotherapeutic agents, but many women may develop chemoresistance linked to the inflammatory process. Interleukin(IL)-12 has been administered in patients with solid tumors, including OC, in an attemp…
Ovarian cancer has the highest incidence in peri-and post-menopausal women and, due to its late diagnosis and poor prognosis, is the fourth most common cause of cancer death. Ovarian cancer responds initially to chemotherapy agents, reducing the growth of tumor mass, however, many women timely develop chemoresistance linked to the inflammatory process. It is undisputed that the risk facto…
Ovarian cancer (OC) is the fifth leading cause of cancer deaths among women and the most lethal gynecological neoplasm due to its late detection, recurrence and metastasis. Evidence suggests that the tumor microenvironment is composed of heterogeneous populations of cells with different levels of malignancy and that tumor development is driven by a subset of specialized cells, characteriz…
Breast cancer (BC) is the most incident tumor and the leading cause of death among women worldwide. In Brazil, the estimate is around 66,280 new cases by the end of 2021. BC is stratified into molecular subtypes depending on markers that may have a better or worse prognosis. Cell lines expressing the estrogen receptor (ER+) and progesterone receptor (PR+) account for 70% of all BC cases. …
Ovarian cancer (OC) has a high incidence after menopause and represents a second most common gynecological cancer, second only to cervical cancer. Initially, OC respond to conventional treatments, like paclitaxel (PTX), thus decreasing the tumor mass growth; however, many women develop chemoresistance linked to immune response, and the disease progress with relapse. Melatonin (N-acetyl-5-…
Ovarian Cancer (OC) is the most lethal gynecological malignancy and the fifth leading cause of Cancer death, mainly due to the resistance to treatments associated with poor prognosis. Melatonin (Mel), an indoleamine secreted by the pineal gland in the circadian cycle dark phase, has shown a number of antitumor properties both in vitro and in vivo. Evidences suggest that Mel exhibit an onc…
Ovarian cancer (OC) has the highest incidence in post-menopausal women and, due to its late diagnosis and poor prognosis, is the fifth most common cause of cancer death worldwide. OC responds initially to conventional chemotherapy, which control tumor growth and progression; however, many women develop chemoresistance linked to the inflammatory process and the disease relapse. Interleukin…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 3 / 3 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 12 / 10 | Completed scholarships in Brazil |
| 18 / 16 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID